Remedent Stock

Remedent Equity

The The Equity of Remedent (REMI) as of Aug 13, 2026 is 2.28 M USD. In the previous year, The Equity was 2.59 M USD — a change of -11.92% (lower).

Equity

2.28 MUSD

YoY

-11.92%

Last updated:

In 2026, Remedent's equity was 2.28 M USD, a -11.92% increase from the 2.59 M USD equity in the previous year.

Access this data via the Eulerpool API

Remedent Stock analysis

What does Remedent do? Remedent Inc is a company specialized in the development, manufacturing, and marketing of innovative dental products. It was founded in 1997 by Jürgen Steenwelle and Philippe de Bergeyck, with its headquarters in Mariakerke, Belgium. The company started with the creation of the GlamSmile veneer system, which revolutionized aesthetic dentistry. Remedent expanded its product portfolio to include teeth whitening systems, dental implants, dental instruments, and dental software solutions. The company aims to revolutionize the dental market with innovative technologies and materials. Remedent works closely with dental professionals worldwide to ensure the highest quality standards. It has locations in Europe, the USA, and Asia. Partnership with dentists and clinics is a key aspect of Remedent's business model, offering training and certifications to ensure proper and effective use of their products. The company is focused on global market expansion through strategic acquisitions and mergers to grow its customer base and promote technological advancements. Remedent has achieved impressive growth and success in a highly competitive market, remaining a significant provider of dental products and pursuing a strong growth strategy. Remedent is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Remedent's Equity

Remedent's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Remedent's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Remedent's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Remedent's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Remedent’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Remedent stock

The Equity of Remedent is 2.28 M USD in 2026.

The Equity of Remedent changed from 2.59 M USD to 2.28 M USD, representing a -11.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Remedent since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Remedent historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Remedent

All Key Metrics — Remedent